MARTINGALE-RISK
Martingale Risk, a specialist in global securities loss recovery, is originating a group action in the Netherlands against Philips on behalf of institutional investors, together with Grant & Eisenhofer as the Global Counsel and Old Haven Funding LLC as the Funder.
As reported by the U.S. regulator, the Food and Drug Administration (FDA), starting from at least October 2015, Philips was notified by customer complaints regarding its respiratory devices (sleep therapy devices used for the treatment of obstructive sleep apnea) causing potential health issues related to foam degradation. Upon receipt of this crucial information, Philips failed to proceed with any appropriate methods of risk analysis and to implement any corrective or preventive actions. Shareholders were not provided with any details regarding the severity of these matters nor the extent that Philips would be harmed financially, which in 2022 already resulted in €486 million in utilized provisions.
Following the June 14th, 2021 recall on millions of respiratory devices to address the health risks related to the foam, the FDA – that classified the recalls as Class I, the most serious type of recall – moved to swiftly investigate Philips, closing their investigation with several critical observations.
In response to an updated safety communication by the FDA, on Sept. 7th, 2023, Philips agreed to pay out at least $479 million to US consumers, as a means of managing and compensating for the health issues caused by its respiratory devices.
On April 4th, 2024, the FDA and the Department of Justice (DoJ) made a joint statement acknowledging Philips’ supposed failure to abide by the instructions and procedures of the remediation plan. This led to a recent Court-approved Consent Decree of Permanent Injunction (filed on April 9th, 2024), whereby Philips’ respiratory devices can no longer be manufactured or distributed from its US facilities, until they comply with various stringent reparative duties, as specified in the Recall Remediation Plan.
The finalization of the Consent Decree is undoubtedly a significant milestone for the protection of US-based consumers, yet action is still needed to further redress Philips’ misconduct, namely for institutional investors who purchased its equities, which were greatly impacted by Philips’ behavior. Martingale Risk, as the originator of the group action, will bring the proceedings in the Netherlands to recover its clients’ investment losses, which occurred throughout the period Nov. 2015-Nov. 2021.
Terms & Conditions:
Martingale Risk, together with Grant & Eisenhofer and Old Haven will be operating on a full contingent fee basis of the recovered amount as all legal, expert costs and expenses will be covered.
How to Proceed/Registration Deadline:
If your firm has invested or traded in Philips common stock and/or ADR from Oct. 30th, 2015-April 24th, 2023, please contact Mr. Marco Delzio (marco.delzio@martingalerisk.com) or Mr. Peter Ogden (peter.ogden@martingalerisk.com) for a free non-binding preliminary analysis.
The deadline to register for the proceedings is July 31st, 2024.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240522190127/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom